Patent ID: 11857574
Assignee: CRISPR THERAPEUTICS AG
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 8:
9. The population of immune cells of claim 6, wherein:
(a) at least 40% of the genetically engineered T cells express the CAR that binds CD70;
(b) at least 50% of the genetically engineered T cells do not express a detectable level of β2M surface protein;
(c) at least 90% of the genetically engineered T cells do not express a detectable TRAC surface protein;
(d) at least 50% of the genetically engineered T cells do not express a detectable CD70 surface protein;
(e) at least 80% of the genetically engineered T cells are Reg1− cells;
(f) at least 80% of the genetically engineered T cells are TGFBRII− cells; or
(g) a combination thereof.